ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2017, Vol. 26 ›› Issue (6): 567-572.DOI: 10.3969/j.issn.1006-298X.2017.06.015

• 论文 • 上一篇    下一篇

接受免疫抑制治疗患者肺孢子菌肺炎的诊治进展

  

  • 出版日期:2017-12-28 发布日期:2017-12-26

Update on pulmonary pneumocystis jirovecii infection in immunosuppressed patients

  • Online:2017-12-28 Published:2017-12-26

摘要:

肺孢子菌肺炎(PCP)是免疫抑制患者最严重的真菌疾病之一,是人类免疫缺陷病毒(HIV)感染者主要的机会性感染。随着糖皮质激素、化疗及其他免疫抑制剂应用的增多,非HIV患者PCP发病率明显增加。这些患者病情更加严重,进展更加迅速,易延误诊治。新的诊断方法出现可提高这些患者的生存率。本文就此做一综述。

关键词: 耶氏肺孢子菌, 免疫抑制, 肺炎

Abstract:

Pneumocystis pneumonia (PCP) is one of the most devastating fungal diseases in immunocompromised patients and remains the primary opportunistic infections in patients infected by human immunodeficiency virus (HIV). In addition, the increasingly frequent use of corticosteroids, chemotherapy, and other immunosuppressive drugs had led to an outbreak of PCP in nonHIVpatients. These patients presenting with PCP have more rapid and severe symptoms, leading to delay the initiation of a specific antiinfective therapy. Fortunately, the contribution of new diagnostic tools and should improve their survival.

Key words: pneumocystis jirovecii, immunocompromised, pneumonia